Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21768255 | 0.83 | SPHK1 (0.45) | CA1CA2SPHK1 | |
| SCHEMBL21768253 | 0.83 | SPHK1 (0.45) | CA1CA2SPHK1 | |
| SCHEMBL22068087 | 0.83 | MAPT (0.47) | NAMPTCYP17A1AURKARPS6KB1MAPKAPK2 | |
| SCHEMBL21781975 | 0.82 | NAMPT (0.50) | NAMPTCYP17A1AURKARPS6KB1MAPKAPK2 | |
| SCHEMBL21137676 | 0.81 | NAMPT (0.50) | CA1NAMPTCYP17A1AURKARPS6KB1 | |
| SCHEMBL21138222 | 0.81 | NAMPT (0.50) | CA1NAMPTCYP17A1AURKARPS6KB1 | |
| SCHEMBL21781781 | 0.81 | NAMPT (0.50) | CA1NAMPTCYP17A1AURKARPS6KB1 | |
| SCHEMBL22068461 | 0.80 | NAMPT (0.48) | CA1CA2NAMPTCYP17A1AURKA | |
| SCHEMBL21781780 | 0.80 | NAMPT (0.47) | CA1CA2NAMPTCYP17A1AURKA | |
| SCHEMBL8245694 | 0.77 | CYP17A1 (0.54) | CA1CA2NAMPTCYP17A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | CA1 1961/4885CA2 3407/4885NAMPT 4254/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | CA1 1961/4885CA2 3407/4885NAMPT 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.